89bio, Inc. (ETNB) Stock Ticker
ETNB right now
Market factors today
Unlock the full ETNB picture
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB stock facts
| Ticker symbol | ETNB |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.2B |
| CEO | Rohan Palekar |
| Employees | 93 |
| Headquarters | San Francisco, CA, US |
| IPO date | 2019-11-11 |
| Website | www.89bio.com |
What you can see for ETNB on Tickr
Live ETNB price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ETNB report.
Rankings
FAQ
What is the ticker symbol for 89bio, Inc.?
The ticker symbol for 89bio, Inc. is ETNB, listed on the NASDAQ Global Market.
What is ETNB?
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of…